The Mayo Clinic Researchers have been working hard on developing a new type of tumor-shrinking procedure with Nanoparticles. Nanoparticles to fight cancer? These nanoparticles produce a potent anti-tumor immune response called HER2-protein.
The results show that the newly designed nanoparticle produced potent anti-tumor immune responses to HER2-positive breast cancers.
has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease.
A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease. Mice that received an injection with the nanoparticle showed a 70 to 80 percent reduction in tumor size. Mice treated with these nanoparticles showed resistance to future tumor recurrence, even when exposed to cancer cells a month later. [Press release from the Mayo Clinic discussing online prepublication in Nature Nanotechnology]
Abstract Circulating Tumor Cells (CTC) and Circulating Tumor Microemboli (CTM) are Circulating Rare Cells (CRC) which herald tumor invasion and are expected to provide an opportunity to improve the management of cancer patients. An unsolved technical issue in the CTC field is how to obtain highly sensitive and unbiased collection of these fragile and heterogeneous cells, in both live and fixed form, for their molecular study when they are extremely rare, particularly at the beginning of the invasion process. We report on a new protocol to enrich from blood live CTC using ISET® (Isolation by SizE of Tumor/Trophoblastic Cells), an open system originally developed for marker-independent isolation of fixed tumor cells. We have assessed the impact of our new enrichment method on live tumor cells antigen expression, cytoskeleton structure, cell viability and ability to expand in culture. We have also explored the ISET® in vitro performance to collect intact fixed and live cancer cells by using spiking analyses with an extremely low number of fluorescent cultured cells. We describe results consistently showing the feasibility of isolating fixed and live tumor cells with a Lower Limit of detection (LLOD) of one cancer cell per 10 mL of blood and sensitivity at LLOD ranging from 83 to 100%.This study provides new protocols for detection and characterization of CTC collected from blood at the very early steps of tumor invasion.
The ISET® technology is the fruit of 20 years of research of Prof. Patrizia Paterlini-Bréchot and her team at the University Paris Descartes and INSERM (Institut National de la Santé et de la Recherche Médicale). Patrizia Paterlini-Bréchot is a Professor of Cellular and Molecular Biology at the University Paris Descartes in Paris, France and Hospital Practitioner at Assistance Publique-Hôpitaux de Paris. As an Oncologist and Hematologist, she and her team have studied cancer since 1982, and more specifically circulating tumor cells since 1995.
‘‘Sentinel’’ Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease
December 22, 2016
Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer. Migration of circulating tumor cells (CTCs) into the blood stream is an early event that occurs during carcinogenesis. We aimed to examine the presence of CTCs in complement to CT-scan in COPD patients without clinically detectable lung cancer as a first step to identify a new marker for early lung cancer diagnosis. The presence of CTCs was examined by an ISET filtration-enrichment technique, for 245 subjects without cancer, including 168 (68.6%) COPD patients, and 77 subjects without COPD (31.4%), including 42 control smokers and 35 non-smoking healthy individuals. CTCs were identified by cytomorphological analysis and characterized by studying their expression of epithelial and mesenchymal markers. COPD patients were monitored annually by low-dose spiral CT. CTCs were detected in 3% of COPD patients (5 out of 168 patients). The annual surveillance of the CTC-positive COPD patients by CT-scan screening detected lung nodules 1 to 4 years after CTC detection, leading to prompt surgical resection and histopathological diagnosis of early-stage lung cancer. Follow-up of the 5 patients by CT-scan and ISET 12 month after surgery showed no tumor recurrence. CTCs detected in COPD patients had a heterogeneous expression of epithelial and mesenchymal markers, which was similar to the corresponding lung tumor phenotype. No CTCs were detected in control smoking and non-smoking healthy individuals. CTCs can be detected in patients with COPD without clinically detectable lung cancer. Monitoring ‘‘sentinel’’ CTC-positive COPD patients may allow early diagnosis of lung cancer.
Abstract This article is a critical note on the subject of Circulating Tumor Cells (CTC). It takes into account the tumor identity of Circulating Tumor Cells as cancer seeds in transit from primary to secondary soils, rather than as a “biomarker”, and considers the help this field could bring to cancer patients. It is not meant to duplicate information already available in a large number of reviews, but to stimulate considerations, further studies, and development helping the clinical use of tumor cells isolated from blood as a modern personalized, non-invasive, predictive test improve cancer patients’ life. The analysis of CTC challenges, methodological bias, and critical issues points out to the need of referring to tumor cells extracted from blood without any bias and identified by cytopathological diagnosis as Circulating Cancer Cells (CCC). Finally, this article highlights recent developments and identifies burning questions which should be addressed to improve our understanding of the domain of CCC and their potential to change the clinical practice.